As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Taysha Gene Therapies, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 9.9%. 16 filings are on record since July 3, 2025 (Schedule 13G/A, August 14, 2026).
Who owns Taysha Gene Therapies, Inc.?
Sell to companies like Taysha Gene Therapies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 32,886,242 · Sole dispositive: 0 · Shared dispositive: 32,886,242 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 16,067,509 · Sole dispositive: 0 · Shared dispositive: 16,244,339 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Vestal Point Capital, LP · Percent: 6.3% · SCHEDULE 13G/A
- · Holder: RTW Investments, LP · Percent: 7% · SCHEDULE 13G/A
- · Holder: Vestal Point Capital, LP · Percent: 5% · SCHEDULE 13G
Taysha Gene Therapies, Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-03. 6 holders' latest filing reports 5% or more of common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.9% | 32,886,242 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RTW Investments, LP | 7% | 20,689,084 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 6.5% | 17,852,291 | SCHEDULE 13G/A, 2026-01-21 | 2025-12-31 |
| Vestal Point Capital, LP | 6.3% | 18,000,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Goldman Sachs Group, Inc. | 5.1% | 12,748,968 | SCHEDULE 13G, 2025-07-03 | 2025-06-26 |
| 5.1% | 16,244,339 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Fmr LLC | 4.9% | 13,528,366 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Octagon Capital Advisors LP | 3.3% | 9,067,500 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Taysha Gene Therapies, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Taysha Gene Therapies, Inc. and the records around it.
Taysha Gene Therapies, Inc. elsewhere on the record
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
Watch Taysha Gene Therapies, Inc.
Get an email when Taysha Gene Therapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Taysha Gene Therapies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Taysha Gene Therapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Taysha Gene Therapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 32,886,242 | 0 | 32,886,242 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 32,886,242 | 0 | 32,886,242 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 32,886,242 | 0 | 32,886,242 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 32,886,242 | 0 | 32,886,242 | SCHEDULE 13G/A, 2026-08-14 |
| Morgan Stanley | 0 | 16,067,509 | 0 | 16,244,339 | SCHEDULE 13G/A, 2026-08-13 |
| Morgan Stanley Capital Services LLC | 0 | 16,001,130 | 0 | 16,001,130 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Taysha Gene Therapies, Inc. by CUSIP 877619106 and gives its principal executive office as 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX 75247 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | The Goldman Sachs Group, Inc. | 5.1% | SCHEDULE 13G |
| 2025-07-16 | BlackRock, Inc. | 5.2% | SCHEDULE 13G/A |
| 2025-08-06 | Fmr LLC | 6.2% | SCHEDULE 13G/A |
| 2025-08-06 | Morgan Stanley | 6.7% | SCHEDULE 13G/A |
| 2025-08-14 | RTW Investments, LP | 9.9% | SCHEDULE 13G/A |
| 2025-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Octagon Capital Advisors LP | 3.3% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 6.5% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 4.9% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 5% | SCHEDULE 13G |
| 2026-02-17 | RTW Investments, LP | 8.3% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 6.3% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 7% | SCHEDULE 13G/A |
| 2026-08-13 | Morgan Stanley | 5.1% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Taysha Gene Therapies, Inc.
Who owns Taysha Gene Therapies, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Taysha Gene Therapies, Inc.: RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), RTW Investments, LP (7%, Schedule 13G/A, filed 2026-05-15), BlackRock, Inc. (6.5%, Schedule 13G/A, filed 2026-01-21), Vestal Point Capital, LP (6.3%, Schedule 13G/A, filed 2026-05-15) and The Goldman Sachs Group, Inc. (5.1%, Schedule 13G, filed 2025-07-03); 1 more is listed above.
Who are the largest shareholders of Taysha Gene Therapies, Inc.?
By the share each holder's latest filing reports, the largest holders of Taysha Gene Therapies, Inc. on this page are RA Capital Management, L.P. (9.9%), RTW Investments, LP (7%) and BlackRock, Inc. (6.5%).
When did RA Capital Management, L.P. buy into Taysha Gene Therapies, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Taysha Gene Therapies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.